Vertex Pharmaceuticals
Presencia
Vertex Pharmaceuticals es una de las ...
Vertex Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización VRTX (US).
Vertex Pharmaceuticals tiene presencia directa en 2 países.
Ellos se encuentran en:
- Biotecnología67%
- Farmacia33%
Fusión, adquisición y financiación con participación de Vertex Pharmaceuticals.
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (publicado el 16 de abril de 2024).
- Vertex Pharmaceuticals has announced the acquisition of ViaCyte (publicado el 13 de julio de 2022).
Ejecutivos
Ver el organigrama con sus 65 ejecutivos principales
Biografías más buscadas en Vertex Pharmaceuticals
- Reshma Kewalramani, Director, President and Chief Executive Officer
- Sangeeta Bhatia, Director
- Jeffrey Leiden, Executive Chairman of the Board
Recientes movimientos de ejecutivos en Vertex Pharmaceuticals
- Nancy Thornberry, se ha incorporado a la empresa como Director (noticia publicada el 6 de diciembre de 2023).
- Michel Lagarde, se ha incorporado a la empresa como Director (noticia publicada el 6 de octubre de 2023).
- Morrey Atkinson que ha sido Senior Vice Presiden and Head of Commercial Manufacturing & Supply Chain, ha ascendido a Executive Vice President, Chief Technical Operations Officer and Head of Biopharmaceutical Sciences & Manufacturing Operations (noticia publicada el 30 de agosto de 2023).
Crear su alerta
para seguir los movimientos de los ejecutivos en Vertex Pharmaceuticals.
Biotecnología
Vertex Pharmaceuticals tiene 2.276 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Histogen has filed for bankruptcy protection (publicado el 19 de abril de 2024).
- Bruker has announced the acquisition of NanoString Technologies (publicado el 18 de abril de 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (publicado el 16 de abril de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Vertex Pharmaceuticals
- Press Releases | Vertex Pharmaceuticals Newsroom
- Vertex Advances VX-548 in Acute and Neuropathic Pain | Vertex Pharmaceuticals Newsroom
- Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease | Vertex Pharmaceuticals Newsroom
- Vertex to Announce Second Quarter 2022 Financial Results on August 4 | Vertex Pharmaceuticals Newsroom
- Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes | Vertex Pharmaceuticals Newsroom
- Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes | Vertex Pharmaceuticals Newsroom
- Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress | Vertex Newsroom
- Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference | Vertex Newsroom
- Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15 | Vertex Newsroom
- Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA | Vertex Newsroom
- View more press releases Close
Redes sociales sobre Vertex Pharmaceuticals
- Vertex Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- Vertex Pharmaceuticals en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Reshma Kewalramani 
Llame a Vertex Pharmaceuticals al +1 617...
